A case of the usage of entecavir to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patient

Takayuki Muraoka, Naruto Taira, Tadahiko Shien, Hiroyoshi Doihara, Akinobu Takaki, Shinichiro Miyoshi

Research output: Contribution to journalArticle

Abstract

Hepatitis B virus (HBV) reactivation is a serious clinical problem for HBV infected patients, and one of its possible causes is chemotherapy for malignant disease. At the onset of active hepatitis, planned chemotherapy should be discontinued and acute or fetal fulminant hepatitis must be induced in some cases. Therefore, it is desirable to prevent virus reactivation during chemotherapy in HBV-positive patients. We report a case in which adjuvant chemotherapy for a breast cancer patient was accomplished safely by using entecavir. The patient was a 48-year-old woman with breast cancer whose HBV infection had been pointed out when she was 20 years old. Breast reconstruction was performed, followed by mastectomy. Pathological findings were invasive ductal carcinoma, three positive nodes, estrogen and progesterone receptor-positive, and HER2-negative. An adjuvant chemotherapy with anthracycline followed by taxane was planned. Blood chemistry revealed the seroconversion of HBV and the quantity of HBV-DNA was 2. 8 log copies/mL. Administration of the anti-virus agent, entecavir, was started three weeks before chemotherapy. The HBV-DNA was decreased under the titer of detection and no re-increase in HBV-DNA was found during chemotherapy. Planned chemotherapy was accomplished safely without HBV reactivation.

Original languageEnglish
Pages (from-to)1861-1864
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume38
Issue number11
Publication statusPublished - Nov 2011

Fingerprint

Hepatitis B virus
Breast Neoplasms
Drug Therapy
Adjuvant Chemotherapy
Hepatitis
DNA
Viruses
entecavir
Ductal Carcinoma
Mammaplasty
Anthracyclines
Mastectomy
Virus Diseases
Progesterone Receptors
Estrogen Receptors

Keywords

  • Entecavir
  • HBV-DNA
  • Hepatitis B virus reactivation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{25762a0fa55d4d69add076a8843f1ee9,
title = "A case of the usage of entecavir to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patient",
abstract = "Hepatitis B virus (HBV) reactivation is a serious clinical problem for HBV infected patients, and one of its possible causes is chemotherapy for malignant disease. At the onset of active hepatitis, planned chemotherapy should be discontinued and acute or fetal fulminant hepatitis must be induced in some cases. Therefore, it is desirable to prevent virus reactivation during chemotherapy in HBV-positive patients. We report a case in which adjuvant chemotherapy for a breast cancer patient was accomplished safely by using entecavir. The patient was a 48-year-old woman with breast cancer whose HBV infection had been pointed out when she was 20 years old. Breast reconstruction was performed, followed by mastectomy. Pathological findings were invasive ductal carcinoma, three positive nodes, estrogen and progesterone receptor-positive, and HER2-negative. An adjuvant chemotherapy with anthracycline followed by taxane was planned. Blood chemistry revealed the seroconversion of HBV and the quantity of HBV-DNA was 2. 8 log copies/mL. Administration of the anti-virus agent, entecavir, was started three weeks before chemotherapy. The HBV-DNA was decreased under the titer of detection and no re-increase in HBV-DNA was found during chemotherapy. Planned chemotherapy was accomplished safely without HBV reactivation.",
keywords = "Entecavir, HBV-DNA, Hepatitis B virus reactivation",
author = "Takayuki Muraoka and Naruto Taira and Tadahiko Shien and Hiroyoshi Doihara and Akinobu Takaki and Shinichiro Miyoshi",
year = "2011",
month = "11",
language = "English",
volume = "38",
pages = "1861--1864",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "11",

}

TY - JOUR

T1 - A case of the usage of entecavir to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patient

AU - Muraoka, Takayuki

AU - Taira, Naruto

AU - Shien, Tadahiko

AU - Doihara, Hiroyoshi

AU - Takaki, Akinobu

AU - Miyoshi, Shinichiro

PY - 2011/11

Y1 - 2011/11

N2 - Hepatitis B virus (HBV) reactivation is a serious clinical problem for HBV infected patients, and one of its possible causes is chemotherapy for malignant disease. At the onset of active hepatitis, planned chemotherapy should be discontinued and acute or fetal fulminant hepatitis must be induced in some cases. Therefore, it is desirable to prevent virus reactivation during chemotherapy in HBV-positive patients. We report a case in which adjuvant chemotherapy for a breast cancer patient was accomplished safely by using entecavir. The patient was a 48-year-old woman with breast cancer whose HBV infection had been pointed out when she was 20 years old. Breast reconstruction was performed, followed by mastectomy. Pathological findings were invasive ductal carcinoma, three positive nodes, estrogen and progesterone receptor-positive, and HER2-negative. An adjuvant chemotherapy with anthracycline followed by taxane was planned. Blood chemistry revealed the seroconversion of HBV and the quantity of HBV-DNA was 2. 8 log copies/mL. Administration of the anti-virus agent, entecavir, was started three weeks before chemotherapy. The HBV-DNA was decreased under the titer of detection and no re-increase in HBV-DNA was found during chemotherapy. Planned chemotherapy was accomplished safely without HBV reactivation.

AB - Hepatitis B virus (HBV) reactivation is a serious clinical problem for HBV infected patients, and one of its possible causes is chemotherapy for malignant disease. At the onset of active hepatitis, planned chemotherapy should be discontinued and acute or fetal fulminant hepatitis must be induced in some cases. Therefore, it is desirable to prevent virus reactivation during chemotherapy in HBV-positive patients. We report a case in which adjuvant chemotherapy for a breast cancer patient was accomplished safely by using entecavir. The patient was a 48-year-old woman with breast cancer whose HBV infection had been pointed out when she was 20 years old. Breast reconstruction was performed, followed by mastectomy. Pathological findings were invasive ductal carcinoma, three positive nodes, estrogen and progesterone receptor-positive, and HER2-negative. An adjuvant chemotherapy with anthracycline followed by taxane was planned. Blood chemistry revealed the seroconversion of HBV and the quantity of HBV-DNA was 2. 8 log copies/mL. Administration of the anti-virus agent, entecavir, was started three weeks before chemotherapy. The HBV-DNA was decreased under the titer of detection and no re-increase in HBV-DNA was found during chemotherapy. Planned chemotherapy was accomplished safely without HBV reactivation.

KW - Entecavir

KW - HBV-DNA

KW - Hepatitis B virus reactivation

UR - http://www.scopus.com/inward/record.url?scp=84856057289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856057289&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 1861

EP - 1864

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 11

ER -